EA200800780A1 - Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq - Google Patents

Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq

Info

Publication number
EA200800780A1
EA200800780A1 EA200800780A EA200800780A EA200800780A1 EA 200800780 A1 EA200800780 A1 EA 200800780A1 EA 200800780 A EA200800780 A EA 200800780A EA 200800780 A EA200800780 A EA 200800780A EA 200800780 A1 EA200800780 A1 EA 200800780A1
Authority
EA
Eurasian Patent Office
Prior art keywords
openers
pyrimidine derivatives
application
potassium channel
kcnq potassium
Prior art date
Application number
EA200800780A
Other languages
English (en)
Inventor
Николай Ханжин
Даниель Родригез Греве
Марио Роттлендер
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200800780A1 publication Critical patent/EA200800780A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к производным пиримидина общей формулы I или их солям и их применению в качестве открывателей калиевых ионных каналов семейства KCNQ, предпочтительно, при лечении эпилепсии.
EA200800780A 2005-09-09 2006-09-07 Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq EA200800780A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09
PCT/DK2006/050039 WO2007065449A1 (en) 2005-09-09 2006-09-07 Pyrimidine derivatives and their use as kcnq potassium channels openers

Publications (1)

Publication Number Publication Date
EA200800780A1 true EA200800780A1 (ru) 2008-06-30

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800780A EA200800780A1 (ru) 2005-09-09 2006-09-07 Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq

Country Status (15)

Country Link
EP (1) EP1937653A1 (ru)
JP (1) JP2009507052A (ru)
KR (1) KR20080043314A (ru)
CN (1) CN101258133A (ru)
AR (1) AR055420A1 (ru)
AU (1) AU2006322461A1 (ru)
BR (1) BRPI0615631A2 (ru)
CA (1) CA2621854A1 (ru)
EA (1) EA200800780A1 (ru)
IL (1) IL189545A0 (ru)
MX (1) MX2008002294A (ru)
NO (1) NO20081713L (ru)
UA (1) UA93387C2 (ru)
WO (1) WO2007065449A1 (ru)
ZA (1) ZA200802174B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008281112A1 (en) * 2007-08-01 2009-02-05 H. Lundbeck A/S Use of KCNQ potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (en) * 2009-02-24 2010-09-02 Neurosearch A/S Substituted pyrimidin derivatives and their medical use
JP5763758B2 (ja) * 2010-07-08 2015-08-12 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
NZ628871A (en) * 2010-10-20 2015-07-31 Gruenenthal Chemie Substituted 6-amino-nicotinamides as kcnq2/3 modulators
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
BR112017008178A2 (pt) * 2014-10-24 2017-12-19 Ono Pharmaceutical Co ativador do canal de kcnq2-5
CN114206328A (zh) * 2019-08-02 2022-03-18 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183335A1 (en) * 2001-02-20 2002-12-05 Piyasena Hewawasam 2, 4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
WO2003068769A1 (en) * 2002-02-12 2003-08-21 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
IL189545A0 (en) 2008-06-05
JP2009507052A (ja) 2009-02-19
CA2621854A1 (en) 2007-06-14
NO20081713L (no) 2008-06-04
ZA200802174B (en) 2009-10-28
KR20080043314A (ko) 2008-05-16
WO2007065449A1 (en) 2007-06-14
MX2008002294A (es) 2008-03-14
UA93387C2 (ru) 2011-02-10
AR055420A1 (es) 2007-08-22
CN101258133A (zh) 2008-09-03
EP1937653A1 (en) 2008-07-02
AU2006322461A1 (en) 2007-06-14
BRPI0615631A2 (pt) 2011-05-24

Similar Documents

Publication Publication Date Title
EA200800780A1 (ru) Производные пиримидина и их применение в качестве открывателей калиевых каналов kcnq
EA200700633A1 (ru) Производные замещённого анилина
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
EA200970575A1 (ru) Соединения на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина и способы их применения
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA201170521A1 (ru) Новые соединения
EA200700286A1 (ru) Применение замещённых производных 2-пирролидона в качестве фунгицидов и инсектицидов
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200870116A1 (ru) Бициклические гетероарильные соединения
EA201101330A1 (ru) Замещенные пиримидины, предназначенные для лечения рака
DK1631295T3 (da) Anvendelse af kondenserede heterocykliske forbindelser som SCCE-inhibitorer ved behandling af hudsygdomme
EA201100447A1 (ru) Органические соединения
ATE510822T1 (de) Kaliumkanalinhibitoren
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
TW200630367A (en) Substituted adenines and the uses thereof
BRPI0720050A2 (pt) 6-oxo-1,6-diidropirimidin-2-ilas no tratamento de doenças proliferativas
EA201100874A1 (ru) Соединения для лечения рака
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
EA201170344A1 (ru) Азаиндольные ингибиторы iap